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A Ab bs st tr ra ac ct t
Despite recent advances in research in hepatocarcinogenesis, we still lack a comprehensive view
of the major pathways involved in liver carcinogenesis. Current concepts suggest that a limited
number of molecular alterations involving oncogene activation and tumor suppressor inhibition
are responsible for initiation of cancer. A recent publication by Zender et al. utilizes a combi-
nation of high-resolution comparative genomic hybridization, short hairpin RNA inhibition of
target genes at the locations of focal genomic deletions, and a primed cell mosaic mouse model to
identify novel tumor suppressors in hepatocellular carcinoma. This exciting new model promises
to provide additional insights into the mechanisms of carcinogenesis.
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I In nt tr ro od du uc ct ti io on n
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third most common cause of death
from cancer [1]. The major risk factors for development of
HCC include chronic hepatitis B (HBV) and hepatitis C virus
infection, high dietary exposure to fungal aflatoxins, and other
disorders causing cirrhosis, such as hereditary hemochro-
matosis, α1-antityripsin deficiency, primary biliary cirrhosis,
non-alcoholic steatohepatitis and alcoholic cirrhosis [2].
Despite significant improvements in our understanding of the
pathogenesis of HCC over the past few decades, we still do not
have a comprehensive understanding of the major molecular
pathogenic processes involved in liver carcinogenesis.
C Ca an nc ce er r   b bi io ol lo og gy y
Current conceptions of carcinogenesis posit that a limited
number of molecular alterations involving oncogene activa-
tion and tumor suppressor inhibition are responsible for the
initiation of the cancer phenotype [3]. The ‘cancer platform’
concept proposes that most oncogenic molecules also have
the inherent ability to activate tumor suppressor genes or
pathways through oncogene-induced apoptosis or senes-
cence, thus limiting their oncogenic effects in a homeostatic
fashion. Oncogene activation is therefore generally only
tumorigenic when it is coupled with inactivation or inhibi-
tion of oncogene-induced pro-apoptotic or senescence path-
ways [4].
The specific effects that lead to inactivation of these pro-
apoptotic or senescence pathways may impinge on major
known tumor suppressors such as p53, but may also be due to
effects on other genes and molecules within the p53 or other
tumor suppressor pathways [5]. These effects may be mediated
through epigenetic or genetic mechanisms. The known risk
factors for HCC are associated with chronic inflammation or
hepatocellular injury. These insults result in repeated cycles of
hepatocyte injury, death and repair that eventually lead to the
premature senescence of the liver [6]. Senescent hepatocytes
lose the telomeric repeats that protect chromosomal ends from
inter- and intra-chromosomal fusion, deletion, rearrangement,
and transposition events that contribute to genomic instability.Loss of telomeres typically triggers cellular apoptosis in the
process referred to as telomeric crisis. Within the population
of senescent hepatocytes, subpopulations may arise that
reactivate telomerase, escape telomeric crisis and become
immortalized [7,8]. These subpopulations, present within
the highly genotoxic inflammatory environment typical of
chronic liver disease, are then at especial risk of acquiring
additional genetic and epigenetic alterations that predispose
them to carcinogenesis. Genomic instability is a hallmark of
the cancer phenotype, and cancer is considered to be a
disease of the cell’s disordered genome.
M Me ec ch ha an ni is sm ms s   a an nd d   p pa at th hw wa ay ys s   i in n   t th he e   p pr ro oc ce es ss s   o of f   l li iv ve er r
c ca ar rc ci in no og ge en ne es si is s
Over the past few decades, multiple approaches have been
used to explore the mechanisms of liver carcinogenesis.
These include: (1) the use of chemical tumor initiators and
promoters in animal models, (2) studies of oncogenic growth
factors, such as insulin-like growth factors and fibroblast
growth factors, (3) the use of transgenic mouse models over-
expressing cytokines, growth factors or oncogenes, such as
transforming growth factor-α (TGF-α), c-Myc, TGF-β, and
platelet-derived growth factor C, either in isolation or in
combination, (4) studies investigating immune-mediated
mechanisms of hepatocellular injury, (5) analyses of molecular
genetic and genomic changes occurring in HCCs, including
allelic imbalance/loss of heterozygosity, gene copy number,
gene mutation, gene methylation and messenger RNA (mRNA)
and microRNA expression, (6) analyses of proteomic
changes and post-translational phosphorylation, glycomic or
sulfation status and (7) studies of the gene alterations
induced by HBV integration and the oncogenic effects of the
protein products of the hepatitis B and C viruses [9].
These studies have revealed multiple mechanisms and
pathways in the carcinogenic process. Pathways identified as
important in hepatocarcinogenesis include the Wnt/β-catenin
signaling pathway, insulin/insulin-like growth factor
pathway, multiple receptor tyrosine kinases activating
downstream of PI3K/Akt and MEK/ERK signaling, and the
TGF-β, interferon-inducible, mTOR and hedgehog signaling
pathways [10-13]. Key tumor suppressor genes identified
thus far include p53, CDKN2A, which encodes p16INK4A and
p14ARF, E cadherin, AXIN1 and AXIN2 [14,15].
A A   n no ov ve el l   a ap pp pr ro oa ac ch h   t to o   i id de en nt ti if fy yi in ng g   l li iv ve er r   t tu um mo or r
s su up pp pr re es ss so or rs s
Recent technological improvements permit the study of
cancer cell genomes at a higher resolution than ever before.
High-resolution array-based comparative genomic hybridiza-
tion allows detailed characterization of the regions of copy
number alterations in tumors [16,17]. This allows the identi-
fication of local regions of copy number gain or loss that may
represent the locations of oncogenes or tumor suppressors.
In this review, we discuss an exciting new model that
promises to provide additional unique insights into the
mechanisms of liver carcinogenesis.
In a recent publication, Zender et al. [18] have combined an
integrated cancer genomic analysis, RNA interference (RNAi)
technology and cancer-susceptible mouse models to discover
and validate tumor suppressor genes contributing to hepato-
cellular carcinoma. The authors analyzed 98 human hepato-
cellular carcinomas of different etiologies. They investigated
the DNA copy number alterations by using representational
oligonucleotide microarray analysis (ROMA) [18], which
allowed them to detect many small and larger deletions.
However, they hypothesized that genomic regions contain-
ing focal deletions were more likely to encode tumor sup-
pressor genes. Consequently, they selected 58 regions
containing small (less than 5Mb) and recurrent deletions for
further analysis. Within these regions, 362 genes were
selected, for which 301 mouse orthologs were identified.
From the Cold Spring Harbor RNAi Codex library, 631 mir-
30-based short hairpin RNAs (shRNAs) targeting the 301
mouse genes (an average of two shRNAs per gene) were
selected. They then performed an in vivo RNAi screen using
a mosaic mouse model, which was formed by subcutaneous
transplantation of immortalized embryonic hepatocytes
lacking p53 and overexpressing Myc. These immortalized
cells are primed for carcinogenesis. The cells were used as a
substrate for screening pools of shRNAs targeting the genes
of interest for development of liver carcinomas. The shRNA
pools were cloned into a plasmid construct co-expressing
green fluorescent protein (GFP), thus facilitating the identi-
fication and characterization of tumors resulting from
shRNA transduction.
Remarkably, most mice transplanted with hepatocytes
transfected with shRNA pools targeting the recurrently
deleted genes developed GFP-positive tumors within a few
weeks of transplantation, compared with control mice trans-
duced with randomly selected shRNAs, which did not
develop an increased frequency of tumors. The integrated
shRNAs present in the most aggressive tumors were then
amplified by polymerase chain reaction and cloned for
subsequent validation. Tumor suppressor genes identified in
this manner included the well-known tumor suppressor
PTEN, the histone chaperone or protein phosphatase
inhibitor gene SET, which is associated with a rare trans-
location in acute myeloid leukemia, as well as a number of
genes not previously identified as tumor suppressors,
including Xpo4, Ddx20, Gjd4, Fstl5 and Nrsn2. The most
enriched shRNA in this study targets exportin 4 (Xpo4),
which belongs to the importin-β family of nuclear trans-
porters. The two known substrates for exportin 4 are the
TGF-β effector SMAD3 and the eukaryotic translation initia-
tion factors EIF5A1 and EIF5A2. Mouse hepatoma cells ex-
pressing shRNAs targeting Xpo4 showed increased total and
phospho-Smad3 in the nucleus, with associated increases in
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the Xpo4 targets Eif5a1 and Eif5a2 also accumulated in the
nucleus after knockdown of Xpo4 in murine hepatoma cells
[18]. Consistent with the putative oncogenic effect of nuclear
EIF5A2, Zender et al. show that EIF5A2 is amplified in
human tumors, stimulates proliferation of XPO4-deficient
tumor cells, and promotes hepatocarcinogenesis in mice.
H Hi is st to or ri ic ca al l   a an nd d   b bi io ol lo og gi ic ca al l   c co on nt te ex xt t   a an nd d   c cl li in ni ic ca al l
i im mp pl li ic ca at ti io on ns s
There are currently very limited therapeutic options for
advanced or metastatic HCC. It is therefore critical to
understand the genetic background and molecular pathways
contributing to intiation and progression of HCC, to aid the
development of rational, targeted therapies [19,20]. The
completion of the human and mouse genome sequences and
the development of methods for cloning integrated sequen-
ces and targeted downregulation of specific mRNAs provide
unique opportunities for screening efforts to identify novel
pathway molecules that contribute to oncogene activation or
tumor suppressor inactivation. Zender et al. [18] used an
elegant primed cell mosaic model to identify novel tumor
suppressors in HCC. While the majority of the newly
identified genes require validation, the careful characteriza-
tion of Xpo4, the most profoundly suppressing gene, provides
novel insight into the gene’s potential roles in carcinogenesis.
The approach used by Zender et al. is particularly
advantageous because it first uses ROMA to narrow down
the field of potential candidate genes, then uses screening
with pools of shRNAs co-expressed with GFP, rather than
the individual shRNAs, thus substantially reducing the cost
and enhancing the efficiency with which tumors induced by
shRNA transduction can be identified.
The variety of genes identified in this study, most of which
have not previously been characterized as tumor suppres-
sors, calls to mind previous debate about the multiplicity of
genes identified at the sites of HBV integration in HBV-
induced HCCs. HBV integrations disrupt the genome, induce
genome instability, and place strong HBV promoter and
enhancer elements adjacent to human genes. These inte-
grations may occur preferentially at genomic sites that are
prone to breakage and rearrangement. The changes induced
by HBV integration may lead to the development and
selection of clones of cells with an increased propensity to
carcinogenesis. Consequently, HBV DNA genomic integra-
tions may represent the natural biological equivalent of the
experimental strategy pursued by Zender et al. The initial
conventional wisdom was that since there were multiple
genes identified at or adjacent to HBV integration sites in
humans, the HBV integration process must be random and
of no significance for hepatocarcinogenesis. More recent
results have identified multiple integrations at the human
telomerase reverse transcriptase (TERT) gene locus, and
suggest that many of the somewhat disparate genes belong
to pathways important for telomerase activation, cellular
calcium signaling or apoptosis [21-24].
The results reported by Zender et al. may, therefore, lead to
the identification of new pathways of significance in the
hepatocarcinogenic process. The complete characterization
and validation of the additional genes identified in this
screen, as well as those from additional screens incorpor-
ating different combinations of predisposing oncogenes and
inactivated tumor suppressors, will be eagerly awaited.
A Ab bb br re ev vi ia at ti io on ns s
GFP, green fluorescent protein; HBV, hepatitis B virus;
HCC, hepatocellular carcinoma; mRNA, messenger
ribonucleic acid; RNAi, RNA interference; ROMA,
representational oligonucleotide microarray analysis;
shRNA, short hairpin RNA; TERT, telomerase reverse
transcriptase; TGF-β, transforming growth factor beta;
Xpo4, exportin 4.
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